Review
Classic therapies revisited
Challenges in changing to non-chlorofluorocarbon inhalers
in the treatment of asthma
T Walleya, P Bundredb, A Rannardb, J Boggb
a University
of Liverpool, Liverpool L69 3GF, UK
Department of Pharmacology and Therapeutics, b Department of Primary Care
Accepted 12 July
1999
The chlorofluorocarbon (CFC)-based metered dose inhaler, which
has been the mainstay of the management of obstructive lung diseases,
will soon be phased out world wide and replaced by CFC-free devices.
Patients will have to be changed to the devices in a co-ordinated
manner to avoid any risk to their health and safety. The different
shapes and aerosol delivery characteristics of the new inhalers, as
well as their distinctive taste, could add to the levels of poor drug
use already experienced in asthma. From previous change scenarios in
disease management, the potential for unstable asthma control is a real
possibility with all the attendant costs. By using the time available
before CFC-based inhalers are withdrawn, there is an opportunity to
enhance asthma management during this period of change.
Keywords: metered dose inhalers; asthma; chlorofluorocarbons
© 1999 by The Fellowship of Postgraduate Medicine
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
